Cargando…
Crystal Ball Health Policies: A Case Against Preventive Testing For Alzheimer’s Disease
After the recent approval of a new drug for the treatment of Alzheimer’s disease, the first in almost twenty years, it is useful to consider what are the real possibilities to make a preclinical diagnosis of dementia and to treat its symptoms. The scientific community widely agrees that the drugs av...
Autores principales: | Inglese, Silvia, Lavazza, Andrea, Abbate, Carlo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886442/ https://www.ncbi.nlm.nih.gov/pubmed/35242026 http://dx.doi.org/10.3389/fnagi.2022.842629 |
Ejemplares similares
-
Research on Alzheimer's syndromes is critical to improve diagnosis, patient management and non-pharmacological treatments, but is under-pursued
por: Abbate, Carlo
Publicado: (2022) -
What Should We Do With People Who Cannot or Do Not Want to Be Protected From Neurotechnological Threats?
por: Inglese, Silvia, et al.
Publicado: (2021) -
Does Soluble TREM2 Protect Against Alzheimer's Disease?
por: Brown, Guy C., et al.
Publicado: (2022) -
A Synergistic Combination of DHA, Luteolin, and Urolithin A Against Alzheimer’s Disease
por: Jayatunga, Dona P. W., et al.
Publicado: (2022) -
Identification of Genetic Networks Reveals Complex Associations and Risk Trajectory Linking Mild Cognitive Impairment to Alzheimer’s Disease
por: Strafella, Claudia, et al.
Publicado: (2022)